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Abstract
Introduction Policy decisions related to orphan and ultra-
orphan drugs challenge traditional decision-making pro-
cesses and often frustrate those affected by them. In gen-
eral, these drugs are associated with significant
uncertainties around clinical benefit, ‘value for money’,
affordability, and ‘adoption/diffusion’, all of which arise
from a lack of available high-quality evidence. Increas-
ingly, patients with rare diseases and their families are
looking for opportunities to contribute to initiatives aimed
at reducing these uncertainties. Therefore, a policy
framework for guiding their involvement is needed to
optimize the impact of any evidence generated.
Objectives The aims of this study were (1) to explore
opportunities for patient involvement in reducing decision
uncertainties throughout the lifecycle of orphan and ultra-
orphan drugs from the perspectives of patients within the
Canadian rare disease community; and (2) to develop a
policy framework for patient input that maximizes the
impact of their involvement on decision uncertainties
around orphan and ultra-orphan drugs.
Methods Two one-day conferences and four workshops
involving patients and/or families from rare disease com-
munities in Canada were held to discuss issues around
orphan and ultra-orphan drug development, access, and
coverage, and identify opportunities for patient input to
reduce related decision uncertainties. Their feedback and
the findings from a recent literature review on patient
involvement in rare diseases were combined into a draft
policy framework based upon Kingdon’s multiple streams
model of decision making. The framework was presented
to a group of patients and other stakeholders, including
providers, pharmaceutical drug plan managers, and indus-
try representatives, and then revised accordingly.
Results Patients and family members/caregivers identi-
fied tangible ways of contributing to the generation of
information at all stages of the drug lifecycle. However, the
proximity of that information to the reduction of a specific
decision uncertainty varied. While the scope of possible
ways mentioned was less broad when compared with the
findings of the literature review, the focus was similar—
capturing the clinical benefit of an orphan or ultra-orphan
drug. A policy framework comprising three stages, each
with a key question and corresponding set of sub-questions
to be asked by patients, was developed. The three main
sequential questions were as follows. (1) What uncertain-
ties need to be addressed? (2) What roles should patients
play? (3) Is each role feasible?
Conclusions Reducing decision uncertainties around
orphan and ultra-orphan drugs requires a policy framework
that explicates when and what type of information needs to
be generated, and recognizes the role of patients as
important sources of such information throughout the
lifecycle of these drugs.
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Key Points for Decision Makers
The challenges involved in making decisions that
affect access to orphan and ultra-orphan drugs
largely stem from considerable uncertainties around
clinical benefit, ‘value for money’, affordability, and
adoption/diffusion.
Based on findings from workshops, Canadian
patients and families within rare disease
communities are keen to contribute to initiatives
aimed at reducing these uncertainties, particularly
those related to clinical benefit.
The Kingdon multiple streams model of decision
making may offer a foundation for constructing a
policy framework that aims to ensure the usefulness
of patient input throughout the lifecycle of orphan
and ultra-orphan drugs.
1 Introduction
Compared with common diseases, rare diseases tend to be
more heterogeneous and involve multiple organs/systems
within the body [1]. Often, their natural history and pro-
gression are not well understood, and knowledge and
expertise in their management among the general medical
community is limited. These factors, coupled with their
low prevalence, challenge traditionally accepted methods
of assessing the efficacy/effectiveness of therapies for rare
diseases (e.g., orphan and ultra-orphan drugs) and, in turn,
the evidence expectations of decision makers involved in
determining access to them.
Compared with common diseases, the annual per-patient
costs of most orphan and ultra-orphan drugs are signifi-
cantly greater [2]. They are also life-long. Although the
number of patients requiring access to any single drug may
be few and the budget impact small, there are thousands of
rare diseases and, collectively, many promising new ther-
apies in development. Increasingly, these therapies repre-
sent disease-modifying treatments for rare diseases in
which current management comprises only supportive care.
Therefore, unmet needs are high, as are uncertainties in (1)
clinical benefit, (2) ‘value for money’, (3) affordability, and
(4) adoption/diffusion of treatments.
Given growing concerns over healthcare system sus-
tainability, there is heightened interest in approaches to
minimizing the ‘risk’ of making wrong decisions on new
health services (including orphan and ultra-orphan drugs),
which lead to wasted healthcare resources and poorer
patient outcomes. Uncertainty drives risk, and arises from a
lack of information to address questions related to factors
such as clinical benefit. Thus, approaches to ensuring that
the right information is collected and available in time to
support decisions are needed.
Patients and families within rare disease communities
have become recognized as key contributors to the devel-
opment of policies throughout the lifecycle of orphan and
ultra-orphan drugs. Highly motivated and experts in their
disease, they represent an important identifiable source of
information about a disease, its impact, and what it might
take to lessen its burden on patients, families, and com-
munities. A recent international review of patient
involvement in rare diseases demonstrates the broad range
of activities in which patients, families, and patient orga-
nizations are already engaged [3].
To optimize the role of those activities within the con-
text of reducing decision uncertainties, a policy framework
for guiding their conceptualization is needed. A compre-
hensive search for such a framework revealed none within
the academic or grey literature.
2 Objectives
This project aimed to:
1. Explore opportunities for patient involvement in
reducing decision uncertainties throughout the lifecy-
cle of orphan and ultra-orphan drugs from the
perspectives of patients within the Canadian rare
disease community
2. Develop a policy framework for patient input that
maximizes the impact of their involvement on decision
uncertainties around orphan and ultra-orphan drugs
3 Methods
This paper builds upon work presented in a companion
paper, describing an inventory of proposed and existing
opportunities for patient input into issues specific to rare
diseases and their management [3]. To explore how those
opportunities could provide information to support deci-
sions affecting access to orphan and ultra-orphan drugs,
they were mapped onto a technology lifecycle–decision
uncertainty matrix. The lifecycle of any technology,
including drugs, comprises six main stages: (1) pre-clini-
cal, (2) clinical trials, (3) regulatory approval, (4) post-
marketing studies, (5) reimbursement, and (6) use in clin-
ical practice. In each stage, evidence that may directly or
indirectly address uncertainties in coverage decision mak-
ing is generated. There are four main types of uncertainties:
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(1) clinical benefit, (2) ‘value for money’, (3) affordability,
and (4) adoption/diffusion. Thus, the matrix offers a
structured approach to linking evidence emerging from
each stage, of which one type is patient input, to a partic-
ular decision uncertainty.
In this paper, the technology lifecycle–decision uncer-
tainty matrix served as the basis for discussions with
patients and families from rare disease communities around
opportunities to contribute to the generation of evidence
that reduces ‘risk’ in coverage decisions on orphan and
ultra-orphan drugs.
3.1 Exploration of the Preferences of the Canadian
Rare Disease Patient Communities Around These
Opportunities
The preferences of patients and families around their
involvement in activities that could generate information to
reduce decision uncertainties were elicited through a multi-
phased approach. Two national one-day conferences and
four workshops (two national and two regional) hosted by
the Canadian Organization for Rare Disorders (CORD)
were held. All of these events brought together patients and
families living with rare disorders in Canada (informally
defined in Canada as a prevalence of \1 in 2,000) and
patient organizations representing them. Participants were
those who responded to an open invitation by CORD. To
increase accessibility to events by all interested patients
and families, travel and accommodations were provided,
where needed.
3.1.1 One-Day Conference #1
The first one-day conference was intended to provide an
overview of the environment within which rare diseases are
currently managed, comparing Canadian experiences with
those in the United States and Europe. International and
local experts representing industry, healthcare providers,
regulators, and payers offered their perspectives on chal-
lenges related to orphan and ultra-orphan drugs. The pre-
sentations were followed by small group sessions with
participants from patient communities (N = 60), who were
asked to discuss the goals of an ‘ideal’ process for man-
aging the development and introduction of new therapies.
Within each group, participants appointed rapporteurs, who
recorded ideas on flip charts. Groups then reconvened to
share their findings and obtain feedback from presenters
and other non-patient stakeholders attending the confer-
ence. An overarching theme of ‘‘sustainable access to
effective therapies’’ emerged. The conference ended with a
discussion around what it might take to achieve such a
goal. It centred on evidence and the need for ongoing
collection of different types of data throughout the lifecycle
of a drug to support the value proposition.
3.1.2 One-Day Conference #2
The second conference, held 4 months later, used the
findings from the first conference to focus on evidence
expectations of regulators and payers. Participants included
patients and families, clinical specialists in rare diseases,
and representatives from industry, Health Canada (federal
regulatory body), and the provincial governments (payers).
Of the patient participants (N = 69), most had attended the
first conference. Those who hadn’t comprised ‘seasoned’
patients and family members who were already familiar
with the issues around orphan and ultra-orphan drugs.
Therefore, all patient participants were considered
‘informed’ members of the rare-disease patient community.
The conference began with presentations on approaches to
addressing existing knowledge gaps related to the screen-
ing, diagnosis, natural history, and progression of rare
diseases; the meaningfulness of outcome measures
(including patient-reported outcomes [PROs]); the appro-
priateness of clinical trial designs for assessing the efficacy
of new therapies; and the use of patient registries for
monitoring clinical benefit in routine clinical practice. The
technology lifecycle–decision uncertainty matrix was then
introduced as a way of systematically considering the
outcomes of different knowledge-producing initiatives,
such as those described in the presentations, within the
context of different decision uncertainties. Participants
were subsequently assigned to small groups comprising
representatives from different stakeholder communities.
Groups were ‘mixed’ to ensure participants heard multiple
perspectives before arriving at shared responses. Each
group completed a common exercise, which involved
mapping the information discussed in the presentations
during the first half of the day onto the technology life-
cycle–decision uncertainty matrix. They identified how
those initiatives were already or could be used to address
specific uncertainties and during which stages in the tech-
nology lifecycle they applied. Groups also identified
remaining gaps once all of the initiatives had been taken
into account. Similar to the first conference, each small
group appointed a rapporteur to report back during a ple-
nary session. In general, groups placed initiatives in the
same ‘cells’ of the matrix. ‘Disease-based patient regis-
tries’ spanned multiple ‘cells’ and became the focus of end-
of-day discussions.
Therefore, the two one-day conferences, collectively,
provided an opportunity for patients and families to
broaden their understanding of issues around orphan and
ultra-orphan drugs and engage in follow-up discussions as
‘informed’ representatives of rare-disease communities.
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3.1.3 First Two Workshops
Two half-day workshops followed the second one-day
conference, and involved only patients and families. Those
who attended the conference were invited to participate.
The purpose of both workshops, each of which included 15
participants, was to explore roles specifically for patients,
families, and patient organizations in reducing decision
uncertainties throughout the technology lifecycle. Both
workshops were facilitated by the same two experienced
researchers. They began with a review of the technology
lifecycle–decision uncertainty matrix. Then, participants
were asked about potential ways in which patients and
families could contribute to the generation of evidence
corresponding to each ‘cell’ of the matrix. ‘Cells’ were
considered by type of decision uncertainty. For example,
participants proposed opportunities for their involvement
in reducing uncertainties in ‘clinical benefit’ of a new
orphan or ultra-orphan drug during each chronological
stage of the technology lifecycle before exploring patient
input into ‘value for money’. To aid discussions, questions
related to each type of uncertainty were presented
(Appendix 1). They came from a recent review of decision
factors/criteria used by centralized drug reimbursement
review processes in the top 22 OECD countries by GDP
[4]. Both workshops were audiotaped and transcribed.
Each workshop resulted in a single patient input-popu-
lated matrix. The two matrices were merged and compared
with that in the companion paper, which originated from an
international review of patient input around rare diseases
[3]. A final matrix that combined opportunities/activities
identified in the companion paper with those emerging
from the workshops was then prepared.
3.1.4 Second Two Workshops
Opportunities/activities appearing in the final matrix were
prioritized by patients and families during two regional
workshops, one in Eastern Canada (Toronto) and one in
Western Canada (Vancouver). Since both took place
alongside CORD regional fora, all patients and families
attending the fora were invited to participate in the work-
shops (Toronto: n = 23; Vancouver: n = 18). None had
been involved in the previous sessions. Therefore, each
workshop began with a summary of the purpose of the
matrix and the steps that led to its development. Facilitators
explained that the range of opportunities/activities com-
prising the matrix is broad, and it would be unreasonable to
expect any single rare-disease patient community to be
engaged in all of them. Thus, there is a need for patient
communities to set priorities. They then asked participants
to examine the opportunities/activities contained in each
cell and identify their top priorities (i.e., ways of being
involved that they felt were most important, as well as
feasible). Participants could identify any number of
opportunities/activities as priorities. They were also asked
to consider the extent to which a single opportunity/activity
could produce information that addressed multiple decision
uncertainties, either directly or indirectly. To facilitate
these discussions, the same set of questions as that used in
the first two workshops were presented (Appendix 1). Once
again, both workshops were audiotaped and transcribed.
The outputs of these two workshops were two populated
matrices of patient-prioritized opportunities for input along
the lifecycle of an orphan or ultra-orphan drug.
To develop an in-depth understanding of how partici-
pants in the four workshops arrived at their decisions,
transcripts from all four workshops were analysed quali-
tatively using a general inductive approach [5, 6]. This
approach is often employed in research that aims to
develop models of the underlying structure of perspectives
or experiences. Two researchers first read through all of the
transcripts and developed initial coding categories, which
represented potential themes. Chunks of text were then
assigned to one or more of these categories. Sub-categories
were created when sub-themes emerged. Examples of sub-
themes included patients’ views towards certain forms of
patient input (e.g., comfort level, feasibility, alignment
with perceptions of facilitators, and barriers to access to
therapies) and their place within existing activities, such as
clinical trial design or the development of natural history
registries. The results of the qualitative analysis were used
to create a version of the matrix that not only contained
priorities of participants in the last two workshops, but also
reflected the views of participants in the first two work-
shops. In addition, they were used to assess the level of
potential impact of each opportunity/activity on a specific
decision uncertainty as either direct or indirect. For
example, participation in clinical trials provides informa-
tion that can directly address uncertainties in clinical
benefit. However, it may only indirectly address uncer-
tainties around adoption/diffusion, since clinical trials are
often restricted to specific patients, who may not reflect the
patient population within a certain jurisdiction. Feedback
on this matrix was sought through a focus group of patients
and families invited to participate in a national summit on
access to orphan and ultra-orphan drugs. Their comments
were incorporated into a final matrix of patient priorities
for involvement.
3.2 Development of a Policy Framework for Involving
Patients in Reducing Decision Uncertainties
Around Orphan and Ultra-Orphan Drugs
Using the Kingdon Multiple Streams Model as the theo-
retical foundation and the elements of a matrix, a policy
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framework for patient input was developed [7]. This is the
underlying basis for the ‘multiple streams’ model of policy
making first put forth by John Kingdon in 1995 [8]. This
model suggests that in order for a policy to be developed
and accepted, there must be a convergence of three
‘streams’. These are the ‘problem stream’ (which asks the
question, ‘‘is the current condition considered a problem?’’
and, therefore, consists of issues that individuals feel need
to be addressed); the ‘policy stream’ (which asks the
question, ‘‘are there policy alternatives that could be
implemented?’’ and, therefore, consists of ideas and
potential solutions that have yet to gain acceptance by
policy communities); and the ‘politics stream’ (which asks
the question, ‘‘are policy-makers willing and able to make
a policy change?’’ and, therefore, consists of acceptability
by policy communities, campaigns by advocacy groups and
potential legislative considerations). When these three
streams converge at a point in time, a ‘policy window’
could open and allow for a policy solution to a problem to
be accepted and implemented.
When applied to rare diseases, the problem stream
comprises the different types of decision uncertainties. The
policy stream represents options for reducing these uncer-
tainties through the engagement of patients at various
stages of the technology life cycle. Finally, the political
stream describes policy communities who need to accept
particular forms of patient involvement if they are to be
implemented. The implementation of certain roles for
patients along the life-cycle will only be possible when
there is a convergence of the three streams.
As part of initial efforts to validate the framework,
views on its structure and content were sought from
Canadian regulators and payers who are part of a multi-
disciplinary research team funded by the Canadian Insti-
tutes for Health Research (CIHR) called ‘Promoting Rare
Disease Innovations through Sustainable Mechanisms
(PRISM)’. Feedback received was incorporated into a
revised version of the framework.
The project was approved by the University of Alberta
Health Research Ethics Board.
4 Results
4.1 Preferences of the Canadian Rare Disease Patient
Communities Around Opportunities Identified
In addition to the final matrix of patient-prioritized
activities described below, the following seven main
themes were identified through the qualitative analyses
of workshop transcripts (Table 1). Each theme is sup-
ported by illustrative quotations from workshop
participants.
4.1.1 Patient Registries
Patient registries were raised on numerous occasions as being
an important tool to monitor rare diseases and their treatments.
‘‘But imagine if there was an international registry
that harmonized parameters. You could probably
drive the p values down and maybe get some HTA
that works.’’
It was felt that registries would be an efficient way of
getting large enough numbers of patients so as to be able to
do meaningful statistics, the lack of which is often an
obstacle to getting an orphan drug funded.
4.1.2 Reimbursement Process
Another theme that emerged in the discussions was the
reimbursement process. In Canada, coverage for orphan and
ultra-orphan drugs is viewed by patients and families as one
of the main issues affecting the rare disease community.
‘‘One of the difficulties, and this comes back to my
own experience, I was denied and I asked if I could
address the committee and the committee of course
said no because they don’t want to see me. They
would much rather just see the paper work because if
they actually saw me, I might be convincing and they
would hate to run against their own initial assess-
ment. And I think patients have certain rights in this
regard and that is that we should be able to address.’’
Other common complaints from the patients included a
lack of an individual patient’s voice during reimbursement
review meetings, the absence of a truly fair appeal process
and opacity in the decision parameters that seem to be used
by committees.
4.1.3 Value Definition
The value definition, which relates to factors considered
when assessing the impact of a therapy on patients, fami-
lies, and the broader community/society, emerged as an
important theme.
‘‘I think you still need the patient… I think the patient
is critical, and the caregiver, to put a framing around
what that means to them versus just the hard core
data.’’
As experts in their own disease, patients and families felt
that they were best able to judge improvements in or wors-
ening health. They expressed concern that the choice of
outcome measures in trials often reflects what is easy to
measure, rather than what is of value to patients and families.
As a result, the trials fail to capture the true value of a therapy.
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4.1.4 Clinical Trials
A prominent theme throughout the four workshops com-
prised the design and conduct of clinical trials.
‘‘Because we’re talking about all the problems that
happen after clinical trials are designed by people
who know the science and the industry, but don’t
know the disease and that’s the problem. We’re
dealing with the problems because we’re not included
before the trial begins.’’
Patients and families were frustrated over the lack of
opportunities for patient input into the design of trials,
given that they are increasingly being asked to help identify
potential patients or participate in the trials themselves.
Table 1 Themes and sub-themes related to patient input identified through patient workshops
Patient registries
Providing data
Providing information on disease and its impact on patients and families through natural history registries
Reporting on outcomes when receiving treatment
Participating in ongoing monitoring and data collection from the moment regulatory approval is obtained
Providing ‘subjective’ data, such as patient-reported outcomes (PROs) and patient satisfaction
Reimbursement process
Providing information on the patient experience
Presenting individual cases, as well as data that is difficult to quantify, through testimonials and presentation to decision makers
Participate in the decision-making process
Providing input in the creation of decision parameters
Funding studies on cost of not funding a drug
Participating on decision-making panels, providing input and clarifying the input from patient submissions
Accepting when evidence of efficacy is insufficient
Right to appeal
Presenting individual case when a negative funding decision has been made
Adding to submissions where information provided by the manufacturer was insufficient
Value definition
Defining value
Defining the meaningfulness of clinical outcome measures
Designing endpoints
Providing input in the creation of endpoints that are relevant, meaningful, and functional
Clinical trials
Designing trials
Setting clinically meaningful endpoints
Setting patient inclusion/exclusion criteria for trial participation
Providing data
Participating in clinical trials
Benefit–harm assessment
Input into benefit–harm trade-off acceptability decisions
Providing information on tolerance
Making final benefit–harm trade-off decision
Early studies and drug discovery
Input into research decisions
Guiding decisions regarding which rare diseases to focus on in research
Managed access
Providing information on the patient experience
Providing input into the design of a structured approach to collecting information on patient experiences
Patient registries
Participating in registries as part of data collection for managed access plans
Stopping criteria
Deciding on stopping criteria with input from a specialist with relevant expertise
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They felt that those involved in the design and conduct of
trials need to recognise the importance of involving
patients in protocol development to not only ensure that
trials incorporate meaningful endpoints, but also optimize
trial participation.
4.1.5 Benefit–Harm Assessment
The fifth theme centred on assessment of benefits and
harms.
‘‘What makes more sense than asking the person
who’s going to bear the risk to help with the risk–
benefit trade-off?’’
Patients and families felt that throughout the technology
lifecycle, decisions around what constitutes acceptable
harm in order to achieve a certain magnitude of benefit are
often made with little input from them. They felt that the
existing paternalistic approach needs to be replaced with
one that recognizes patients and families as empowered
equal partners in such decisions.
4.1.6 Early Studies and Drug Discovery (R&D)
For many patients and families living with rare diseases,
there are no treatments beyond supportive care. Therefore,
the need for research that could lead to the development of
new therapies was a dominant theme shared by all four
workshops. Given that resources available for research are
limited, patients and families felt that they should have a
role in setting research funding priorities to ensure that
decisions reflect a comprehensive understanding of the
potential implications of different proposals.
‘‘…well, a lot of foundations that I work with, so they
don’t fund basic research they only fund tools to
advance drugs.’’
4.1.7 Managed Access
The final theme related to managed access as a decision
option for payers. Briefly, managed access comprises a
conditional funding option, which makes therapies avail-
able to eligible patients on the basis of an agreement. The
terms of the agreement may include collection of certain
types of data or specific clinical or financial outcomes that
must be achieved in order to receive continued funding.
‘‘Could there be a time, like let’s say this is a new
drug, there’s not enough information, could there be
in the framework that why not do a study those who
want to try the new drug? Not everyone wants to try a
new drug. Everybody’s just assuming that everybody
wants this. Some want it, some stay on the other. Do a
comparative study and then decide.’’
Two other themes were noted: ‘public and patient
awareness’, and ‘patient experts’. Neither was included in
the list of themes, since workshop participants placed them
outside the technology lifecycle–decision uncertainty
matrix. It was clear that more awareness of rare diseases
and their implications is needed across patient communities
and the general public. While it may be possible that
increased awareness could impact decision uncertainties,
its role in reducing a particular uncertainty at a particular
step of the life cycle was not clear to participants. With
respect to ‘patient experts’, participants felt that it was
important they be recognized as experts in their disease by
other stakeholder communities.
The final matrix of patient-identified priorities for their
involvement is presented in Table 2. The organization of
the elements in each cell uses the themes presented in
Table 1. Patient registries were identified by the patients as
a necessary way in which they could contribute to the
reduction of all four existing uncertainties throughout the
life cycle. They also felt strongly that the value of a drug
should be defined by patients, and that this would likely
reduce the uncertainties at the clinical trials step, the reg-
ulatory approval step, the post-marketing step, and the
reimbursement decision-making step. They also felt that
they ought to be able to provide their views on benefit–
harm trade-offs, and to establish tolerance levels for a
specific drug. Finally, they felt that there should be means
of providing new orphan drugs under ‘managed access’
programs; that is, by providing data during the period when
the drug is made available to them, and agreeing on stop-
ping criteria (when the patient will stop the drug) with
input from a relevant specialist physician.
4.2 Policy Framework for Involving Patients
in Reducing Decision Uncertainties Around
Orphan and Ultra-Orphan Drugs
A framework for determining when and how to involve
patients in generating information to reduce uncertainties
in decision making on orphan and ultra-orphan drugs using
Kingdon’s multiple streams model is presented in Fig. 1. It
begins with recognition of a decision problem (‘problem
stream’) by one stakeholder group. Evidence confirming
the problem is then gathered and presented to all stake-
holder groups. Once consensus on the problem is achieved,
the underlying uncertainty (e.g., clinical benefit, value for
money, etc.) and the stages in the lifecycle from which it
arises are identified. Subsequently, policy alternatives are
considered (‘policy stream’). These refer to role(s) for
patients in reducing the uncertainties that they deem








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































114 D. Menon et al.
acceptable. Using the matrix presented in Table 2, an ini-
tial list of potential roles corresponding to the relevant
type(s) of uncertainty and stage(s) in the lifecycle is first
generated. For each role, a series of questions intended to
provide insights into its acceptability by patients are then
asked. These questions relate to patients’ willingness to be
involved in this way, their previous experiences in similar
roles, and the availability of any required resources. Based
upon patients’ responses to the questions, a short list of
‘acceptable’ roles is created. Once patient consensus
around the list is obtained, it moves onto the final phase,
political acceptance (political stream’). During this phase,
decision makers, along with other stakeholder communi-
ties, assess the acceptability of each role on the short list
from their perspective. Legislative considerations and
financial implications are also taken into account during
deliberations in order to arrive at acceptable and feasible
roles for patients.
5 Discussion
The workshops reiterated the fact that rare disease patients
in Canada are more than willing to engage in various
activities throughout the life cycle of an orphan or ultra-
orphan drug. They actively identified potential opportuni-
ties whereby they could contribute information on any
stage of the life cycle that might help reduce uncertainties
that physicians and regulatory and reimbursement decision
makers are often challenged by. The most pressing con-
cern, in their view, was uncertainty in the knowledge on the
clinical benefit of a treatment for a rare disease. This
uncertainty which arises often from small-scale clinical
trials, often ties the hands of regulators and payers. How-
ever, the patients and caregivers at the workshops offered a
number of suggestions as to how they could help reduce
this particular uncertainty. One direct way to achieve this is
by increasing participation in clinical trials, which patients
proposed they do. One other suggestion was that patients
have an active early role in specifying the relevant outcome
measures for clinical trials.
As far as the uncertainty in value for money was con-
cerned, the patients felt that their contributions would be
limited to reducing the uncertainty in clinical benefit,
which is most often the ‘value’ component of value for
money. By and large, patients felt that they had little
control over the ‘money’ component, and so did not think
they could have any influence on it.
The patients also felt that they could play a role in
reducing the uncertainty in the affordability of a treatment.
They proposed doing this by continuing to provide clinical
data during the reimbursement stage. One way of doing this


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Developing a Patient-Directed Policy Framework 115
continuous monitoring of individual patients which could
reduce the inappropriate use of a treatment which proves
ineffective for some patients.
What has been referred to as ‘opportunities’ for patients
and patient organizations are really the contents of the
policy stream within a multiple streams model of policy
making. Whether any of these potential solutions to reduce
uncertainty actually gets accepted by policy makers
depends on the politics stream and the problem stream,
whose contents are the uncertainties. All of this will be
highly context-dependent. In some jurisdictions, rare-dis-
ease patient engagement of the types described here are
much more advanced than in some other jurisdictions. This
is due at least in part to the fact that policy windows have
opened from time to time, and policy makers have listened
to the stakeholders and found the political environment to
be receptive to changes.
In Canada, research of the type reported in this (and the
earlier [3]) paper has, in recent years, shown that the
problem stream (uncertainties about rare disease and its
management) and the policy stream, at least from the
patients’ perspective (activities that they are willing to
participate in) have been clearly elucidated. At the same
time, there is heightened awareness by Canadian govern-
ments and society more generally, about the challenges of
managing rare diseases. The federal government is cur-
rently developing an orphan drug regulatory framework
and the provincial and territorial governments have estab-
lished a working group to develop a pan-Canadian
approach to funding orphan and ultra-orphan drugs. From
the perspective of the Kingdon model of policy develop-
ment, it would appear that there will be opportunities for
policy windows to open, and new policies regarding orphan
and ultra-orphan drugs implemented.
6 Conclusions
While the importance of patient input into policy decisions
has become widely recognized, the objective of that input
is not always clear. In this paper, we defined the roles of
patients as key producers of evidence and, in turn,
knowledge needed to reduce different types of decision
uncertainties that arise during the life cycles of orphan and
ultra-orphan drugs. These uncertainties, some of which




• How was the decision problem idenﬁed? (e.g., paents, records of decisions)
• What evidence demonstrang that this is a decision problem exists?
• Do all stakeholders agree on the decision problem?
• What are the main types of uncertaines surrounding decision problem?
• From which stages in the technology life cycle do the uncertaines arise?
• What is known about paents’ willingness to be involved in generang 
evidence to reduce uncertainty at the relevant stages?
• How have paents been involved in these stages?
• How are paents currently involved in these stages?
• What is known from paent experiences about their involvement at these 
stages?
Policy Formaon
• What role(s) would paents like to play in each of these stages?
• Has this been tried elsewhere, and if yes, what is known about their 
experience?
• What resources would be required?
• Are those resources available?
• Is each role acceptable to decision-makers?
• Is each role acceptable to other stakeholder communies?
• What legislave consideraons need to be taken into account?
• Are there any addional ﬁnancial implicaons?
What uncertaines need to be reduced?
What role(s) should paents play?
Is each role feasible?
Fig. 1 Proposed policy framework for patient input into reducing decision uncertainties
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history and epidemiology of most rare diseases, and some
from the treatments themselves, are considerable.
Where traditional forms of evidence and expertise are
lacking, patients, as experts in their disease and its indi-
vidual and social impact, may play critical roles. We pro-
posed a framework that aims to enhance the effectiveness
of patient involvement by connecting roles to explicit
decision needs and assessing their acceptability and feasi-
bility from the perspectives of multiple stakeholders.
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Appendix 1: Questions related to each type
of uncertainty
Clinical benefit
(a) Are the benefits observed in the trial generalizable to
the patient population within the relevant jurisdiction?
(b) Does the level of health gain observed vary across
patient subtypes?
(c) Which outcomes should be measured?
(d) What is the natural progression of the disease?
(e) What is known about the effect of the drug compared
to that of current best practice?
(f) What is the meaningfulness to patients of the health
gain attributable to the drug?
Value for money
(g) What are the broader implications associated with the
drug, beyond clinical benefit?
(h) What opportunity costs are associated with funding
the drug?
(i) What is known about society’s willingness to pay for
the expected gain?
Affordability
(j) How many patients are expected to benefit from the
drug?
(k) What is the expected cost per patient per year?
Adoption/diffusion
(l) How will access to the drug be managed?
(m) Who has the expertise to decide on starting and
stopping criteria?
(n) Are mechanisms compelling patients and physicians
to ensure appropriate use required?
(o) Are there other drugs in the pipeline that may affect
utilization of this drug in the near future?
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